ABL Bio Announces Preclinical Data for Multiple Myeloma-Targeting 'ABL101'

ABL Bio CI (Photo by ABL Bio)

[Asia Economy Reporter Chunhee Lee] Bispecific antibody company ABL Bio announced on the 29th that it will present preclinical data of 'ABL101' in a poster session at the 'Antibody Engineering & Therapeutics' conference held in San Diego, USA, from the 4th to the 8th of next month (local time).

ABL101 is a bispecific antibody candidate applying ABL Bio's immuno-oncology bispecific antibody platform ‘Grabody-T’. It simultaneously targets B-cell maturation antigen (BCMA), which is overexpressed in multiple myeloma, and 4-1BB, which is involved in T-cell activation. Like other Grabody-T-based pipelines, it stimulates 4-1BB signaling only in the tumor microenvironment where BCMA is expressed, enhancing the tumor-killing function of T cells. Currently, it has completed toxicity testing in monkeys and is preparing to enter Phase 1 clinical trials next year.

At this conference, ABL Bio will present a poster on the anticancer efficacy of ABL101 confirmed in mouse models and the inhibitory effect on the growth of allogeneic cancer cells through immune memory response. The data also include T-cell activation and tumor-killing effects confirmed by combination administration of ABL101 and the T cell engager BCMAxCD3 bispecific antibody.

Lee Sang-hoon, CEO of ABL Bio, said, “Through continuous research and development (R&D) investment and presenting achievements on the international stage, we will establish ourselves as a leading company in the global bispecific antibody market.”

This content was produced with the assistance of AI translation services.